The major players in the lysosomal storage disease treatment market include Shire PLC, Pfizer, Inc., Sanofi, BioMarin Pharmaceutical Inc., Actelion Ltd., Raptor Pharmaceutical Corp., ProtalixBiotherapeutics Inc., Amicus Therapeutics, Inc.
The growing number of people with lysosomal disorders and increased awareness about the various treatment options available will be the major drivers for this market. Enhanced diagnosis and rise in research and development activities for treating LSD will boost the growth of this market. Stem cell transplant is a certain treatment method used to treat LSD and advanced research in this area will further propel the market growth. A rise in the storage of stem cells will greatly benefit market growth. COVID-19 pandemic will not impact this market since LSDs are genetic disorders unaffected by viruses. The major hindrances of this market are high treatment cost and many undiagnosed cases due to its heterogeneous nature.
The entire lysosomal storage disease treatment market has been sub-categorized into indication, type of therapy and end-user. current and future demand for lysosomal storage disease treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.
By Indication
- Gaucher’s Diseases
- Fabry Diseases
- Pompe’s Syndrome
- Mucopolysaccharidosis
- Others
By Type of Therapy
- Enzyme Replacement Therapy
- Stem Cell Therapy
- Substrate Reduction Therapy
- Others
By End User
- Hospitals
- Clinics
Source: https://www.valuemarketresearch.com/report/lysosomal-storage-disease-treatment-market
Naira Shekhawat has been into Content Writing just after completing her Graduation in English Literature. Her love for words has won her many accolades in her respective jobs ever since. Naira covers business sections for VMR News. She is a traveller by heart and loves writing on food blogs as a freelancer.